Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Derek Alderson
No relevant relationships to disclose
Matthew Guy Nankivell
No relevant relationships to disclose
Sally Patricia Stenning
Research Funding - UK Medical Research Council
Jane M. Blazeby
No relevant relationships to disclose
Michael Griffin
No relevant relationships to disclose
Adrian Crellin
No relevant relationships to disclose
Heike I. Grabsch
Research Funding - CancerResearch UK
Stephen Falk
No relevant relationships to disclose
Alicia Frances Clare Okines
Honoraria - Roche
Other Remuneration - Roche
Claire Robb
No relevant relationships to disclose
Ruth E Langley
Research Funding - UK Medical Research Council